Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641256 | 0.96 | MAOA (0.42) | MAOAHTR2ASIGMAR1MAOB | |
| SCHEMBL5642021 | 0.94 | MAOA (0.41) | MAOAHTR2ASIGMAR1MAOB | |
| SCHEMBL5641436 | 0.91 | HTR2A (0.37) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL5641607 | 0.81 | CYP1A2 (0.41) | MAOASIGMAR1CYP2A6TAAR1LOXL2 | |
| SCHEMBL6000698 | 0.80 | FAAH (0.41) | GRIK1SMN1; SMN2SLC6A3 | |
| SCHEMBL2093740 | 0.79 | DAO (0.38) | MAOASIGMAR1GRIK1SMN1; SMN2SLC6A3 | |
| SCHEMBL6002903 | 0.76 | FAAH (0.46) | — | |
| SCHEMBL9462841 | 0.75 | CYP19A1 (0.38) | SIGMAR1GRIK1 | |
| SCHEMBL6222556 | 0.75 | CYP1A2 (0.41) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL2097333 | 0.75 | CES1 (0.39) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | GLRA2, CACNG5, GLRB | MAOA 2232/4885HTR2A 390/4885SIGMAR1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.